-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PDYdb1jjEARXriTnhRn1h6Y2IXYKcbhw7wDc4uuzu9fyww7XxqPaaw68Y67ht8AV dJ5s07aVd8hunLtRAffTfQ== 0000950133-01-501803.txt : 20010710 0000950133-01-501803.hdr.sgml : 20010710 ACCESSION NUMBER: 0000950133-01-501803 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20010630 ITEM INFORMATION: FILED AS OF DATE: 20010706 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HUMAN GENOME SCIENCES INC CENTRAL INDEX KEY: 0000901219 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 223178468 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 001-14169 FILM NUMBER: 1675853 BUSINESS ADDRESS: STREET 1: 9410 KEY W AVE CITY: ROCKVILLE STATE: MD ZIP: 20850-3338 BUSINESS PHONE: 3013098504 MAIL ADDRESS: STREET 1: 9410 KEY WEST AVE CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 w51263e8-k.txt FORM 8-K 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ----------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 JUNE 30, 2001 ------------- Date of Report (Date of earliest event reported) HUMAN GENOME SCIENCES, INC. --------------------------- (Exact Name of Registrant as Specified in Charter) DELAWARE 0-022962 22-3178468 ------------------------------- ------------------------ -------------------------------- (State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification No.) Incorporation)
9410 KEY WEST AVENUE, ROCKVILLE, MARYLAND 20850-3338 ----------------------------------------------------- (Address of Principal Executive Offices) (ZIP Code) Registrant's telephone number, including area code: (301) 309-8504 -------------- (Former Name or Former Address, if Changed Since Last Report) 2 ITEM 5. OTHER EVENTS. On July 2, 2001, Human Genome Sciences announced that the exclusivity period for its human gene therapeutic consortium expired on June 30, 2001, a period described as the initial research term. None of the consortium members chose to extend the initial research term. Upon expiration of the initial research term, work already initiated by the members can continue if evidence of continued diligence is provided, but no new use of Human Genome Sciences' technology is permitted by the members. Collectively, the members are actively pursuing approximately 430 programs involving approximately 280 different genes for the creation of small molecule and antibody drugs. They also are developing approximately 30 therapeutic protein drugs. Human Genome Sciences can provide no assurance that any of these programs will result in approved drugs, or if approved, that any of the drugs can be successfully commercialized. If any of these programs result in drugs that are commercialized, Human Genome Sciences will be entitled to certain milestone and royalty payments. In addition, for drugs developed by GlaxoSmithKline, Human Genome Sciences will be entitled to certain co-promotion rights. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HUMAN GENOME SCIENCES, INC. Date: July 6, 2001 By: /s/ James H. Davis, Ph.D. ----------------------------------------- James H. Davis, Ph.D. Senior Vice President and General Counsel -----END PRIVACY-ENHANCED MESSAGE-----